SAN FRANCISCO – In the wake of President Obama making a brief fundraising stop here during his election campaign, center stage now falls to the more than 110 biotech execs who have gathered in the city to make their presentations to investors at the annual BIO Investor Forum (BIF). Read More
The one-of-a-kind lawsuit filed last Wednesday against the FDA by Toronto-based Apotex Inc. (joined by the company's U.S. arm, Apotex Corp.) probably will be resolved quickly, said Kurt Karst, director at Hyman, Phelps & McNamara in Washington. Read More
From a public health perspective, the response to an influenza pandemic is a race against an emerging virus. And in that race, the virus has several advantages. Read More
BRUSSELS, Belgium – Continuing the habit of starting the day's proceedings with unexpected musical choices, the audio-visual technician in charge of the Silver Hall meeting room chose Louis Armstrong's and Ella Fitzgerald's inimitable rendition of "Let's call the whole thing off" to kick off Tuesday's sessions at the BioPartnering Future Europe meeting at the Square Brussels Meeting Centre Tuesday. Read More
• Gliknik Inc., of Baltimore, raised $4.9 million in Series B financing. Baxter Ventures, an initiative created last year by Baxter International Inc., led the round and is joined by existing investors. Read More
• AtheroNova Inc., of Irvine, Calif., said it is supporting an additional preclinical study at the David Geffen School of Medicine at the University of California, Los Angeles, to expand the uses of compounds to regress atherosclerotic plaque under its pending patents. Read More
• Oculus Innovative Sciences Inc., of Petaluma, Calif., said results of its open-label pilot study testing Microcyn Technology-based Atrapro Antipruritic Hydrogel in combination with Neosalus Cream in atopic dermatitis demonstrated a statistically significant 50 percent reduction in the body surface area of the atopic dermatitis from baseline to week four. Read More
• Foundation Medicine Inc., of Cambridge, Mass., signed a multiyear agreement with Eisai Co. Ltd., of Tokyo, for genomic profiling and diagnostic discovery in a multisite, international clinical trial testing an Eisai therapeutic candidate. Read More
